Ads
related to: new afib drugswexnermedical.osu.edu has been visited by 10K+ users in the past month
262 Neil Avenue # 430, Columbus, Ohio · Directions · (614) 221-7464
- Should I See a Heart Doc
Talk to your doc about your heart
and learn what to ask
- Patient Testimonials
Hear from our patients
about their Ohio State experience
- Prepare For Your Visit
What to bring to your visit
plus heart & vascular resources
- Find a Doctor
Meet with our experts to diagnose
your symptoms and receive treatment
- Should I See a Heart Doc
explorepanel.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Antiarrhythmic agents, also known as cardiac dysrhythmia medications, are a class of drugs that are used to suppress abnormally fast rhythms (tachycardias), such as atrial fibrillation, supraventricular tachycardia and ventricular tachycardia.
It has clinical advantages over other class III antiarrhythmics in chemical cardioversion of atrial fibrillation, and maintenance of sinus rhythm, and does not have the pulmonary or hepatotoxicity of amiodarone, however atrial fibrillation is not generally considered life-threatening, and dofetilide causes an increased rate of potentially life ...
A new drug application (NDA) for the approval of apixaban was submitted to the US Food and Drug Administration (FDA) by Bristol-Myers Squibb (BMS) and Pfizer jointly after the conclusion of the ARISTOTLE clinical trial in 2011. [26] [12] Apixaban was approved for the prevention of stroke in people with atrial fibrillation in December 2012.
AFib, the most common heart rhythm disorder, is linked to a 39% increased risk of cognitive impairment, while coronary heart disease increases the risk of dementia by 27%, with up to 50% of heart ...
Atrial fibrillation is associated with an increased risk of heart failure, dementia, and stroke. [3] [12] It is a type of supraventricular tachycardia. [14] Atrial fibrillation frequently results from bursts of tachycardia that originate in muscle bundles extending from the atrium to the pulmonary veins. [15]
Clinical trials have compared dronedarone to placebo and to amiodarone, for its ability to reduce atrial fibrillation, to reduce mortality overall and from cardiac causes, and for its adverse effects, including excess mortality. [5] [9] Dronedarone is a non-iodinated class III anti-arrhythmic drug which helps patients return to normal sinus rhythm.
Ads
related to: new afib drugswexnermedical.osu.edu has been visited by 10K+ users in the past month
262 Neil Avenue # 430, Columbus, Ohio · Directions · (614) 221-7464
explorepanel.com has been visited by 10K+ users in the past month